FTSE 100 movers: Miners weigh heavily after Chinese data disappoints
30th Sep 2013 14:19
Mining stocks declining sharply today on the back of the disappointing data from the world's top metals user, China. Fresnillo, Anglo American, Antofagasta, Glencore Xstrata and Rio Tinto were all falling sharply. China´s manufacturing sector purchasing managers´ index (PMI) for the month of Septe
Read moreGSK sells thrombosis drug brands to Aspen Pharmacare
30th Sep 2013 13:29
GlaxoSmithKline (GSK) is selling its thrombosis drug brands and a related factory to South Africa's biggest generic drug maker Aspen Pharmacare for 700m pounds. The drug company has decided to let go of its Arixtra and Fraxiparine brands after experiencing falling sales. GSK said the disposal wou
Read moreTuesday broker round-up UPDATE
17th Sep 2013 08:56
Aggreko: Credit Suisse reduces target price from 2000p to 1400p and downgrades from neutral to underperform. Antofagasta: WH Ireland downgrades to neutral. Associated British Food: Nomura moves target price from 1650p to 1670p staying with its reduce rating. Aviva: Berenberg downgrades from hold
Read moreFriday broker round-up UPDATE
13th Sep 2013 08:26
ASOS: Panmure Gordon raises target price from 4555p to 5950p maintaining a buy recommendation. AstraZeneca: Jefferies reduces target price from 3200p to 2850p and retains a hold recommendation. Barclays: Jefferies initiates with a target price of 367p and a buy recommendation. Barratt Development
Read moreBroker tips: GlaxoSmithKline, Glencore Xstrata, Whitbread
11th Sep 2013 11:23
Panmure Gordon has kept its positive stance on pharmaceuticals group GlaxoSmithKline, despite recent concerns over rising competition from generic versions of its Advair drug, recommending investors to 'buy' on weakness. The broker said that there are still a number of regulatory process steps and
Read moreBroker snap: 'Buy' Glaxo despite fears over generics, says Panmure
11th Sep 2013 09:42
Panmure Gordon has kept its positive stance on pharmaceuticals group GlaxoSmithKline, despite recent concerns over rising competition from generic drugs, recommending investors to 'buy' on weakness. GSK's share price sunk 2.5% on Tuesday after the US Food and Drug Administration (FDA) published dra
Read moreLondon pre-open: Stocks seen higher as Syria concerns recede
11th Sep 2013 07:47
Stocks are expected to edge higher on Wednesday morning as tensions over Syria continue to ease. Markets rose strongly on Tuesday after Syria accepted a Russian proposal to hand over all chemical weapons to international control in an attempt to avoid US military action. In a nationally televised
Read moreGSK and Theravance receive FDA approval for COPD treatment in US
11th Sep 2013 07:04
GlaxoSmithKline (GSK) has, alongside partner Theravance, announced that the US Food and Drug Administration's (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) has recommended approval of their latest treatment for chronic obstructive pulmonary disease (COPD) in the US. The committee voted
Read moreLondon close: Stocks jump to four-week high as Syria concerns ease
10th Sep 2013 16:40
The FTSE 100 jumped to a four-week high on Tuesday as investors' fears of an impending US military strike on Syria eased and the economic outlook for China improved. London's benchmark index finished 53.25 points higher at 6,583.99, a gain of 0.82%; the last time it closed higher was on August 14th
Read moreFTSE 100 movers: easyJet leaps on CEO interview
10th Sep 2013 14:39
easyJet shares are firmly on the rise, extending yesterday's gain of around one per cent. The company has said it's geared up to take on other low-cost airlines across Europe, saying it expects other airlines will have difficulty in embracing a no-frills style. It said the loss of as many as 86m sho
Read moreGlaxo blockbuster Advair faces US copycats after FDA greenlight
10th Sep 2013 11:54
A report from the US drugs regulator has threatened to open up competition for GlaxoSmithKline's best-selling drug. Shares in the pharmaceuticals giant fell more than 3% after a report from the US Food and Drug Administration (FDA) suggested generic drugs identical to GSK's blockbuster asthma drug
Read moreLondon midday: FTSE 100 nears one-month high
10th Sep 2013 11:39
Receding fears about a potential US military strike on Syria and decent data from China lifted UK stocks on Thursday morning, with the FTSE 100 rising to levels not seen in nearly a month. London's benchmark index was up 0.8% at 6,581.91 by midday; the last time it closed higher was on August 14th
Read moreTuesday broker round-up UPDATE
10th Sep 2013 08:17
African Barrick Gold: Investec shifts target price from 135p to 137p, while downgrading from hold to sell. Aquarius Platinum: JP Morgan moves target price from 39p to 49p, while downgrading from neutral to underweight. Citi lowers target price from 66p to 54p and downgrades from buy to neutral. As
Read moreFTSE 100 movers: BG falls after warning on Egypt
9th Sep 2013 18:29
Oil and gas group BG was a heavy faller today after lowering its 2014 production milestones due to the instability in Egypt, delays to the start-up of production in Norway and low natural gas prices in the US. Food ingredients peer and retail group Associated British Foods was also lower despite s
Read moreLondon close: BG Group drags FTSE 100 lower, Syria concerns weigh
9th Sep 2013 17:44
The FTSE 100 dropped into the red on Monday, pulling back after hitting a three-week high the previous session, as heavy falls from natural gas giant BG Group and ongoing concerns about Syria pressured stocks lower. London's benchmark index finished 16.59 points lower at 6,530.74, falling 0.25% fro
Read more